Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Montelino Therapeutics Inc. operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This action is being processed in 1 distinct art unit, which suggests a specific technical field for the company's active patent applications. This focus indicates that the company is likely pursuing protection for a specific therapeutic candidate or a closely related group of biological technologies.
The prosecution is overseen by 1 distinct examiner, COLEMAN, BRENDA LIBBY. As the busiest examiner, COLEMAN, BRENDA LIBBY is responsible for 1 busiest examiner pending action. This examiner handles the entirety of the portfolio's current pending matters, centralizing the company's immediate prosecution efforts under this individual's review. For the company, this means that the immediate future of their intellectual property depends on the specific examination criteria and feedback provided by this single examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COLEMAN, BRENDA LIBBY | 1 | 74.9% | +15.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | COLEMAN, BRENDA LIBBY | 27d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18504472 | BI-FUNCTIONAL COMPOUNDS AND METHODS FOR TARGETED UBIQUITINATION OF ANDROGEN RECEPTOR | COLEMAN, BRENDA LIBBY | 1624 | §112 | Non-Final OA | 27d | Pending | Nov 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial